Becton Dickinson & Co Stock Price, News & Analysis

Becton, Dickinson and Company (NYSE: BDX) has announced tender offers to purchase up to $500 million of its outstanding debt securities. The offers include several series of securities with varying due dates ranging from 2027 to 2050. Holders must tender their securities by 5:00 p.m. on August 19, 2022, to be eligible for early tender payment. The tender offers will expire on September 2, 2022. The total consideration for securities will be determined based on fixed spreads over U.S. Treasury securities. This move aims to manage debt effectively amid changing market conditions.

BD (Becton, Dickinson and Company) has partnered with Direct Relief and the National Association of Community Health Centers (NACHC) to allocate $1.08 million to four community health centers. This funding aims to improve chronic disease management for underserved populations. Each center will receive $270,000 to enhance culturally sensitive care and pharmacist-led education. The initiative, part of the BD Helping Build Healthy Communities program, has supported 52 centers since 2013, totaling $22.6 million in contributions.

BD (Becton, Dickinson and Company) reported revenue of $4.6 billion for Q3 2022, a 0.7% increase year-over-year. Base revenue growth was 6.0%, with a notable decline in COVID-only testing revenues to $76 million from $300 million previously. GAAP diluted EPS was $1.28, while adjusted EPS rose 16.7% to $2.66. The company raised its full-year revenue guidance to approximately $18.75-$18.83 billion, reflecting 8.75%-9.25% growth, and adjusted EPS guidance to $11.28-$11.35. BD's ongoing acquisitions and innovations support its growth strategy amid macroeconomic challenges.

BD (Becton, Dickinson and Company) has acquired MedKeeper, a provider of cloud-based pharmacy management applications, enhancing its commitment to Smart, Connected Care. This strategic acquisition aims to optimize IV workflow by integrating MedKeeper's solutions into BD's existing medication management offerings. The move addresses the growing need for customizable pharmacy software in light of COVID-related challenges. The transaction is expected to have an immaterial impact on BD's fiscal 2022 financial results.

BD (Becton, Dickinson and Company) has launched a new molecular PCR test for the monkeypox virus, now available for research use outside the U.S. This test leverages the BD MAX™ System, providing fast and efficient results for laboratories. The BD MAX™ platform can process up to 24 samples in under three hours. This initiative, developed in partnership with CerTest Biotec, aims to enhance research capabilities amidst a global health emergency declared by the World Health Organization. This test is critical for understanding and controlling the spread of monkeypox.

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, payable on September 30, 2022, to shareholders on record as of September 9, 2022. This results in an annual dividend rate of $3.48 per share, reflecting the company's commitment to returning value to its shareholders. BD continues to advance global health through innovative medical technology, ensuring safety and efficiency in healthcare delivery.

BD (Becton, Dickinson and Company) has completed its acquisition of Parata Systems, enhancing its presence in the pharmacy automation market valued at $600 million, projected to grow to $1.5 billion within a decade.

This acquisition aligns with BD's innovation strategy and aims to drive smart, connected care. The Parata portfolio will augment BD's Medication Management Solutions, addressing industry challenges such as clinician shortages and increased demand on pharmacy services.

BD (Becton, Dickinson and Company) will report its financial results for the third quarter of fiscal year 2022 on August 4, 2022, at 6:30 a.m. ET. The report will include summary financial information from the quarter ending June 30, 2022. An audio webcast will follow at 8 a.m. ET, discussing the results and operational updates. BD remains a leading global medical technology company, committed to improving health care through innovative solutions and technologies.